<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539458</url>
  </required_header>
  <id_info>
    <org_study_id>CS0005-P</org_study_id>
    <nct_id>NCT03539458</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification</brief_title>
  <official_title>Feasibility Study of the Tendyne Mitral Valve System for Use in Subjects With Mitral Annular Calcification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-arm, multi-center feasibility clinical study of the&#xD;
      Tendyne Mitral Valve System for the treatment of eligible subjects with symptomatic, severe&#xD;
      mitral regurgitation and severe mitral annular calcification (MAC). Subjects satisfying the&#xD;
      study inclusion/exclusion criteria will undergo a procedure to implant the Tendyne mitral&#xD;
      valve replacement device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Actual">November 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite Endpoint of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs), as Classified by the Clinical Events Committee (CEC)</measure>
    <time_frame>30 days post implant</time_frame>
    <description>Definition of Device Success:&#xD;
All of the following must be present:&#xD;
Absence of procedural mortality or stroke; and&#xD;
Proper placement and positioning of the device, and&#xD;
Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and&#xD;
Continued intended safety and performance of the device, including:&#xD;
i. No evidence of structural or functional failure&#xD;
ii. No specific device-related technical failure issues or complications&#xD;
iii. Reduction of MR to either optimal or acceptable levels without significant structural valve dysfunction and with no greater than mild (1+) paravalvular MR (and without associated hemolysis).&#xD;
All device- or procedure-related adverse events will be adjudicated by an independent clinical events committee</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Insufficiency</condition>
  <condition>Mitral Annular Calcification</condition>
  <condition>Mitral Annulus Calcification</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Valve Heart Disease</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Heart Valve Calcification</condition>
  <condition>Mitral Valve Disease</condition>
  <arm_group>
    <arm_group_label>Device Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo procedure with the Tendyne Mitral Valve System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tendyne Mitral Valve System</intervention_name>
    <description>Mitral valve replacement</description>
    <arm_group_label>Device Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Heart Team determines subject is not a suitable candidate for conventional surgical&#xD;
             treatment due to degree of MAC present and the subject will likely benefit from&#xD;
             transcatheter valve implantation&#xD;
&#xD;
          2. Symptomatic, severe mitral regurgitation, as defined in the 2017 ACC expert Consensus&#xD;
             Decision Pathway on the Management of MR&#xD;
&#xD;
          3. NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory)&#xD;
&#xD;
          4. Age 18 years or older at time of consent&#xD;
&#xD;
          5. Not a member of a vulnerable population per the investigator's judgment&#xD;
&#xD;
          6. The subject or the subject's legal representative has been informed of the nature of&#xD;
             the study and agrees to its provisions, including complying with study required&#xD;
             testing and follow-up visits, and has provided written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Presence of Left Ventricle or Left Atrium thrombus&#xD;
&#xD;
          2. Chest condition that prevents transapical access&#xD;
&#xD;
          3. Left Ventricular Ejection Fraction (LVEF) less than 25% assessed by echocardiogram&#xD;
&#xD;
          4. Left Ventricular End Diastolic Dimension (LVEDD) &gt; 7.0 cm&#xD;
&#xD;
          5. Severe mitral stenosis not amenable to balloon valvuloplasty or transcatheter therapy&#xD;
&#xD;
          6. Prior intervention with permanently implanted mitral device (e.g. MitraClip)&#xD;
&#xD;
          7. Mitral pathoanatomy and Left Ventricular Outflow tract (LVOT) anatomy deemed not&#xD;
             suitable for Tendyne mitral valve implantation&#xD;
&#xD;
          8. Any planned cardiac surgery or intervention that is 30 days prior and 30 days post&#xD;
             that is not concomitant with the Tendyne procedure&#xD;
&#xD;
          9. Cardiac resynchronization therapy (CRT) device or implantable pulse generator (IPG)&#xD;
             implanted within three months of planned implant procedure&#xD;
&#xD;
         10. Myocardial Infarction (MI) within 30 days of the planned implant procedure&#xD;
&#xD;
         11. Symptomatic, or ischemia-associated coronary artery disease (e.g., active ischemia)&#xD;
             amenable to revascularization and thus requiring stenting or CABG&#xD;
&#xD;
         12. Cerebrovascular accident (CVA) within six months of planned implant procedure&#xD;
&#xD;
         13. Unresolved severe symptomatic carotid stenosis (&gt; 70% by ultrasound)&#xD;
&#xD;
         14. Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support&#xD;
             devices within 1 month prior to planned implant procedure&#xD;
&#xD;
         15. Severe tricuspid regurgitation or severe right ventricular dysfunction&#xD;
&#xD;
         16. Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis or any other&#xD;
             structural heart disease causing heart failure other than dilated cardiomyopathy of&#xD;
             either ischemic or non-ischemic etiology&#xD;
&#xD;
         17. Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding&#xD;
             diathesis, or coagulopathy if cannot be adequately treated&#xD;
&#xD;
         18. History of endocarditis within 6 months of planned implant procedure&#xD;
&#xD;
         19. Active systemic infection requiring antibiotic therapy&#xD;
&#xD;
         20. Known hypersensitivity or contraindication to procedural or post-procedural&#xD;
             medications (e.g., contrast solution, anti-coagulation therapy) which cannot be&#xD;
             adequately managed medically&#xD;
&#xD;
         21. Subject unable or unwilling to take anticoagulation with warfarin for a minimum of 6&#xD;
             months following Tendyne valve implantation&#xD;
&#xD;
         22. Known hypersensitivity to nickel or titanium&#xD;
&#xD;
         23. Subject is undergoing hemodialysis due to chronic renal failure ( ≥ Stage 4 CKD)&#xD;
&#xD;
         24. Subject has pulmonary arterial hypertension (fixed PAS &gt;70mmHg)&#xD;
&#xD;
         25. FEV1 &lt; 50% of predicted or &lt; 1L&#xD;
&#xD;
         26. Subject refuses blood transfusions&#xD;
&#xD;
         27. Subject has COPD requiring continuous home oxygen therapy or chronic outpatient oral&#xD;
             steroid use&#xD;
&#xD;
         28. Pregnant, lactating, or planning pregnancy within next 12 months.&#xD;
&#xD;
         29. Currently participating in an investigational drug or another device trial that has&#xD;
             not reached its primary endpoint&#xD;
&#xD;
         30. Subjects with non-cardiac co-morbidities that are likely to result in a life&#xD;
             expectancy of less than 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sorajja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute - Abbott Northwestern Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kartik Sundareswaran, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Structural Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 26, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03539458/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was initially designed to register up to 30 patients from 10 investigational sites in the U.S. However only 11 patients were actually registered and underwent successful implantation with Tendyne TMVI device. Of the 11 patients, 10 patients completed 30-day follow-up, while the remaining one patient died 18 days after the implant procedure</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Device Arm</title>
          <description>All subjects will undergo a procedure with the Tendyne Mitral Valve System: Mitral valve replacement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Device Arm</title>
          <description>All subjects will undergo a procedure with the Tendyne Mitral Valve System: Mitral valve replacement</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.2" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Predicted Surgical Mortality</title>
          <description>The Society of Thoracic Surgeons' risk model predict the risk of operative mortality &amp; morbidity after adult cardiac surgery. Risk models were developed for nine specific endpoints, including operative mortality. Operative mortality includes both (1) all deaths occurring during the hospitalization, even if after 30 days (2) deaths occurring after discharge, but within 30 days of the procedure. Therefore, a patient's mortality risk score is defined as the patient's predicted risk of operative mortality as calculated by the specific operative mortality statistical model.</description>
          <units>Probability percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.03" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Insufficiency (GFR &lt; 60 mL/min/1.73m^2)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Coronary Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Valve Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Measurement</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Left Ventricular End Diastolic Volume (LVEDV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.3" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ventricular End Systolic Volume (LVESV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Measurement</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Left Ventricular End Diastolic Diameter (LVEDD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ventricular End Systolic Diameter (LVESD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kansas City Cardiovascular Questionnaire</title>
          <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL) within a 2-week recall period. Scores are scaled 0-100, where a score of 100 represents the lowest burden of symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest &amp; discomfort is increased with physical activity.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NYHA Functional Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Functional Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Endpoint of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs), as Classified by the Clinical Events Committee (CEC)</title>
        <description>Definition of Device Success:&#xD;
All of the following must be present:&#xD;
Absence of procedural mortality or stroke; and&#xD;
Proper placement and positioning of the device, and&#xD;
Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and&#xD;
Continued intended safety and performance of the device, including:&#xD;
i. No evidence of structural or functional failure&#xD;
ii. No specific device-related technical failure issues or complications&#xD;
iii. Reduction of MR to either optimal or acceptable levels without significant structural valve dysfunction and with no greater than mild (1+) paravalvular MR (and without associated hemolysis).&#xD;
All device- or procedure-related adverse events will be adjudicated by an independent clinical events committee</description>
        <time_frame>30 days post implant</time_frame>
        <population>The number of participants analyzed includes all subjects that were registered and implanted in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Device Arm</title>
            <description>All subjects will undergo a procedure with the Tendyne Mitral Valve System: Mitral valve replacement</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs), as Classified by the Clinical Events Committee (CEC)</title>
          <description>Definition of Device Success:&#xD;
All of the following must be present:&#xD;
Absence of procedural mortality or stroke; and&#xD;
Proper placement and positioning of the device, and&#xD;
Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and&#xD;
Continued intended safety and performance of the device, including:&#xD;
i. No evidence of structural or functional failure&#xD;
ii. No specific device-related technical failure issues or complications&#xD;
iii. Reduction of MR to either optimal or acceptable levels without significant structural valve dysfunction and with no greater than mild (1+) paravalvular MR (and without associated hemolysis).&#xD;
All device- or procedure-related adverse events will be adjudicated by an independent clinical events committee</description>
          <population>The number of participants analyzed includes all subjects that were registered and implanted in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Device Arm</title>
          <description>All subjects will undergo a procedure with the Tendyne Mitral Valve System: Mitral valve replacement</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paravalvular Leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia or conduction disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Worsening Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Mesenteric Ischemia and Hemorrhagic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke/TIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory insufficiency/Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia or Conduction Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Heart Failure treated with IV diuretics</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vocal Cord Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigators will not use study-related data without the written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Reshma Rao, Principal Study Clinical Research Associate</name_or_title>
      <organization>Abbott Vascular Structural Heart</organization>
      <phone>651-756-2542</phone>
      <email>reshma.rao@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

